Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 3 | $0.85 | $0.90 | $0.88 |
| Q2 2026 | 3 | $0.91 | $0.95 | $0.93 |
| Q3 2026 | 3 | $1.02 | $1.13 | $1.08 |
| Q4 2026 | 1 | $0.54 | $0.59 | $0.57 |
| Q1 2027 | 1 | $0.93 | $1.01 | $0.96 |
| Q2 2027 | 1 | $0.92 | $1.00 | $0.96 |
| Q3 2027 | 1 | $1.12 | $1.22 | $1.17 |
| Q4 2027 | 1 | $0.55 | $0.59 | $0.57 |
GSK Plc last posted its earnings results on Wednesday, April 29th, 2026. The company reported $1.24 earnings per share for the quarter, topping analysts' consensus estimates of $1.16 by $0.08. The company had revenue of 7.63 B for the quarter and had revenue of 32.67 B for the year. GSK Plc has generated $6 earnings per share over the last year ($5.56 diluted earnings per share) and currently has a price-to-earnings ratio of 13.68. GSK Plc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 04/29/2026 | Q1 2026 | $1.16 | $0.86 | -0.3 | $7.76 B | $7.63 B |
| 02/04/2026 | Q4 2025 | $0.64 | $0.84 | 0.2 | $8.47 B | $8.62 B |
| 10/29/2025 | Q3 2025 | N/A | $1.00 | N/A | $8.20 B | $8.55 B |
| 07/30/2025 | Q2 2025 | N/A | $0.72 | N/A | $7.70 B | $7.99 B |
| 04/30/2025 | Q1 2025 | $1.08 | $0.80 | -0.28 | $7.51 B | $7.52 B |
| 02/05/2025 | Q4 2024 | $0.44 | $0.20 | -0.24 | $7.62 B | $8.12 B |
| 10/30/2024 | Q3 2024 | $1.16 | -$0.03 | -1.19 | $8.02 B | $8.01 B |
| 07/31/2024 | Q2 2024 | $1.00 | $0.58 | -0.42 | $7.56 B | $7.88 B |
| 05/01/2024 | Q1 2024 | N/A | $0.52 | N/A | $8.89 B | $7.36 B |
| 01/31/2024 | Q4 2023 | $0.76 | $0.17 | -0.59 | N/A | $8.05 B |
| 11/01/2023 | Q3 2023 | $1.09 | $0.72 | -0.37 | N/A | $8.15 B |
| 07/26/2023 | Q2 2023 | $0.87 | $0.80 | -0.07 | N/A | $7.18 B |
| 04/26/2023 | Q1 2023 | $0.82 | $0.74 | -0.08 | N/A | $6.95 B |
| 02/01/2023 | Q4 2022 | $0.59 | $0.74 | 0.15 | N/A | $7.38 B |
| 11/02/2022 | Q3 2022 | $0.96 | $5.38 | 4.42 | N/A | $7.83 B |
| 07/27/2022 | Q2 2022 | $0.76 | $0.42 | -0.34 | N/A | $6.93 B |
| 04/27/2022 | Q1 2022 | $0.96 | $0.90 | -0.06 | N/A | $7.19 B |
| 02/09/2022 | Q4 2021 | $0.81 | $0.38 | -0.43 | N/A | $9.53 B |
| 10/27/2021 | Q3 2021 | $1.00 | $0.58 | -0.42 | N/A | $6.63 B |
| 07/28/2021 | Q2 2021 | $0.64 | $0.70 | 0.06 | N/A | $5.84 B |
In the previous quarter, GSK Plc (:GSK) reported $1.24 earnings per share (EPS) to beat the analysts' consensus estimate of $1.16 by $0.08.
The conference call for GSK Plc's latest earnings report can be listened to online.
The conference call transcript for GSK Plc's latest earnings report can be read online.
GSK Plc (:GSK) has a recorded annual revenue of $32.67 B.
GSK Plc (:GSK) has a recorded net income of $5.72 B.GSK Plc has generated $5.64 earnings per share over the last four quarters.
GSK Plc (:GSK) has a price-to-earnings ratio of 13.68 and price/earnings-to-growth ratio is 0.15.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED